GlycoNex and PrecisemAb announced a technology licensing agreement to develop a new generation of an anti-glycan antibody drugs aimed at increasing antibody specificity, reducing drug side effects, and enhancing treatment outcomes for a variety of solid tumors. Under the agreement, GlycoNex will license PrecisemAb's Universal Antibody Lock (UAL) technology platform, which modifies antibodies to inhibit their activity until activated by tumor proteases. Deploying UAL in conjunction with GlycoNex's anti-glycan antibody platform offers the potential to improve antibody drug behavior by enabling precisely therapeutic effects on tumors, while enhancing the safety and tolerability of such drugs by reducing side effects caused by on-target, off-site binding.

The Universal Antibody Lock technology was invented by Professor Tain-Lu Cheng's team at Kaohsiung Medical University and exclusively licensed to PrecisemAb. This technology can be widely applied in the fields of monoclonal antibody drugs, antibody-drug conjugates (ADCs), and bispecific antibodies, with a production process similar to that of conventional antibodies. The UAL platform is protected by patents in 18 countries.